A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT05243550 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder Cancer
Urothelial Carcinoma
Urothelial Carcinoma Bladder

Interventions

DRUG: UGN-102

Sponsor

UroGen Pharma Ltd.